Maganin CAR-T don Myasthenia Gravis (MG)

Myasthenia Gravis (MG) cuta ce ta jijiyoyin jijiyoyi masu rauni wadda ke faruwa sakamakon cututtukan autoantibodies (musamman anti-acetylcholine receptor antibodies, AchRAb) wanda ke lalata sadarwa tsakanin jijiyoyi da tsokoki, wanda ke haifar da rauni mai canzawa, ptosis, dysphagia, da kuma a cikin mawuyacin hali mai barazanar rayuwa. Ga marasa lafiya da ke da MG masu hana garkuwar jiki waɗanda suka kasa maganin rigakafi na gargajiya, IVIG, FcRn inhibitors, da kuma masu hana kari, zaɓuɓɓukan magani sun kasance kaɗan.

Maganin BIOOCUS mai manufa biyu CD19/BCMA CAR-T yana wakiltar wani sabon maganin ƙwayoyin cuta na autologous wanda ke kawar da ƙwayoyin B masu cutarwa da ƙwayoyin plasma waɗanda ke da alhakin samar da ƙwayoyin rigakafi na autoantibody, yana ba da damar samun gafara mai zurfi da dorewa a cikin MG mai wahalar magani.

Maganin CAR-T don MG wani ci gaba ne na rigakafi wanda aka ƙera ƙwayoyin T na majiyyaci don bayyana masu karɓar antigen na chimeric (CARs) waɗanda ke nufin duka CD19 (akan ƙwayoyin B) da BCMA (akan ƙwayoyin plasma). Bayan faɗaɗawa a cikin dakin gwaje-gwaje, ana sake saka waɗannan ƙwayoyin CAR-T masu manufa biyu cikin majiyyaci, inda suke rage ƙwayoyin rigakafi masu aiki da kansu waɗanda ke tuƙa MG, ta haka suna rage matakan AchRAb da kuma dawo da aikin jijiyoyin jini.

Wannan hanyar da aka yi niyya ta hanyoyi biyu tana magance duka sassan ƙwayoyin halitta da na humoral na amsawar autoimmune, tana samar da cikakken sake saita tsarin garkuwar jiki idan aka kwatanta da hanyoyin magani guda ɗaya ko na gargajiya.

• Inganta alamun cikin sauri da ɗorewa: Rage gajiyar tsoka, ptosis, diplopia, dysarthria, da raunin gaɓɓai.
• Zurfin ƙwayoyin B da raguwar ƙwayoyin plasma: Raguwa mai alama da ɗorewa a cikin AchRAb da jimlar adadin B-lymphocyte.
• Inganta sakamakon asibiti: Ribar da aka samu a sakamakon Quantitative Myasthenia Gravis (QMG) da Activities of Daily Living (ADL).
• Bayanin tsaro mai kyau: An jure shi sosai ba tare da an lura da wata cuta ta sakin cytokine (CRS) ko kuma gubar jijiyoyi a cikin shari'o'in da aka yi wa magani ba.
• Yiwuwar yin afuwa na dogon lokaci: Yana rage ko kawar da buƙatar rage ƙarfin garkuwar jiki na yau da kullun.
• Keɓancewa & daidaitacce: Yana amfani da ƙwayoyin halittar majiyyaci, yana rage haɗarin ƙin yarda.

1. Cutar sankarar bargo– Tattara ƙwayoyin T na majiyyaci ta hanyar amfani da jinin da ke kewaye.
2. Injiniyan Halitta– Ana gyara ƙwayoyin T don bayyana CD19 da BCMA CARs kuma ana faɗaɗa su a cikin cibiyoyin GMP.
3. Kwandishan (idan ana buƙata)- Takaitaccen aikin lymphostasis don inganta aikin CAR-T.
4. Jiko na CAR-T– Jiko ɗaya ta hanyar jijiya ta CD19 CAR-T (0.5×10⁶/kg) + BCMA CAR-T (1×10⁶/kg).
5. Sa ido da kuma bin diddigi- Kimantawa akai-akai na faɗaɗa CAR-T, matakan AchRAb, ƙididdigar ƙwayoyin B, maki QMG/ADL, da aikin gabobin jiki har zuwa watanni 12+.

• Tsarin CD19/BCMA CAR-T mai inganci mai matakai biyu wanda aka inganta musamman don cututtukan da ke da alaƙa da garkuwar jiki.
• Ƙungiyar masana'antar GMP ta duniya da ƙwararrun masu ilimin rigakafi waɗanda ke da ƙwarewa a fannin cututtukan jini da kuma cututtukan da ke haifar da garkuwar jiki.
• Cikakken tallafin marasa lafiya na ƙasashen duniya: haɗin kai tsakanin harsuna da yawa, canja wurin filin jirgin sama, masauki, da kuma bin diddigin marasa lafiya na dogon lokaci.
• An tabbatar da tarihin CAR-T don cututtukan da ke haifar da garkuwar jiki (gami da SLE) da kuma tsarin magani na musamman.
• Kulawa mai cikakken tsari tun daga tantancewa kafin magani zuwa sa ido bayan allurar.